Halozyme Therapeutics, Inc. (HALO) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $108.17 +1.93%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $18.4 million versus the consensus estimate of $13.71 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Vireo Growth completes acquisition of C21 Investments
- UBS Upgrades Apollo Tyres (APTY:IN) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
